India, March 20 -- Eli Lilly and Company (India) on Thursday announced the launch of its globally popular weight-loss injectable drug, Mounjaro, in India. Adults taking the drug with diet and exercise in a controlled clinical trial lost on average 21.8kg at the highest dose and 15.4kg at the lowest dose over a period of 72 weeks, said the company.

The single-dose vial presentation has marketing authorization from the national drugs regulator-Central Drugs Standard Control Organization (CDSCO). The drug is already widely popular in US, UK and European markets.

According to the company statement, it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polyp...